{"nct_id":"NCT02229396","title":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","status":"COMPLETED","status_verified_date":"2018-12","start_date":"2014-09-04","start_date_type":"ACTUAL","primary_completion_date":"2016-04-26","primary_completion_date_type":"ACTUAL","completion_date":"2017-12-28","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["AZN"]}